After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Gilead will pay $202 million to resolve claims that it paid kickbacks to healthcare providers in the form of honoraria, meals ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Exclusive: World Health Organisation says shortage of most commonly used Aids drug caused by withdrawal of US foreign aid ...

NEW YORK (Reuters) -Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the ...

On April 22, the CDC allegedly informed Emory University in Atlanta that its large HIV self-testing program was being ...

The South accounts for nearly half the nation's new HIV diagnoses. Prevention programs are trying to stem the tide, and in Dallas County, they're working — but now they're facing funding cuts.

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Two new ways of giving the HIV medicine Dolutegravir to newborn babies have been found to be safe and effective, according to ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...